Semaglutide or tirzepatide? How to think about choosing a GLP-1

Semaglutide and tirzepatide are the two molecules behind most of the GLP-1 conversation right now, and people searching for one almost always end up comparing it to the other. This article walks through how they work, what head-to-head research has actually found, and the factors that go into a provider's decision, so you have a real framework rather than a single verdict. It is educational content, not medical advice.

What is the best GLP-1 for weight loss?

There is no single answer to this that applies to everyone, and any content that gives you one number without asking about your health history is skipping a step. Semaglutide and tirzepatide are both effective, well-studied options, and which one makes sense for a given person depends on their goals, medical history, tolerance for side effects, response to treatment if they have tried a GLP-1 before, and practical factors like cost and access. A licensed provider reviewing your history is genuinely in a better position to answer "which GLP-1 is best for weight loss" for you than a general article is, which is why this piece explains the tradeoffs rather than picking a winner.

How semaglutide and tirzepatide work

Semaglutide, the active ingredient in Ozempic and Wegovy, is a GLP-1 receptor agonist. It mimics a naturally occurring gut hormone called glucagon-like peptide-1, which slows stomach emptying, reduces appetite, and affects insulin release, contributing to weight loss and blood sugar control.

Tirzepatide, the active ingredient in Mounjaro and Zepbound, works on two receptors instead of one. It is a dual GIP and GLP-1 receptor agonist, meaning it acts on both the GLP-1 pathway described above and a second gut hormone pathway, glucose-dependent insulinotropic polypeptide (GIP), which is involved in insulin secretion and metabolism [1]. The added GIP activity is the mechanistic reason tirzepatide is sometimes described as a "dual-acting" medication, and it is part of why researchers designed a direct trial comparing the two.

Both medications are given as a once-weekly subcutaneous injection with a gradual dose titration schedule over several months, a similarity that matters when people are comparing how each fits into daily life; the difference between them is mechanistic and, as the next section covers, reflected in average trial outcomes, not in how often or how you take either one.

Ozempic, Wegovy, Mounjaro, and Zepbound are trademarks of their respective manufacturers, Novo Nordisk and Eli Lilly. Luvo Health is not affiliated with, endorsed by, or sponsored by either company.

What head-to-head research shows

The most direct comparison comes from SURMOUNT-5, a 72-week, head-to-head, open-label trial of 751 adults with obesity but without diabetes, published in the New England Journal of Medicine, which randomized participants to tirzepatide or semaglutide at their maximum tolerated doses [2]. At 72 weeks, the tirzepatide group lost an average of 20.2% of body weight, compared with 13.7% for the semaglutide group [2]. Nearly a third of people on tirzepatide, 32%, reached a weight-loss target of 25% or more, compared with 16% of people on semaglutide [2]. Tirzepatide also showed somewhat greater improvements in some cardiometabolic measures, including blood pressure and cholesterol markers, at 72 weeks [3].

Real-world data adds some nuance. A retrospective study using US electronic health record data on people who started tirzepatide or semaglutide for obesity found a similar direction of effect over 6 months, generally consistent with the trial's findings, though real-world results tend to run lower than clinical-trial results across GLP-1 medications generally, since adherence and dosing outside a trial setting vary more [4].

These are average, group-level results, not a promise about any individual's outcome. Results vary considerably from person to person, and a trial average does not predict how a specific person will respond to either medication. It's also worth knowing that both molecules have their own independent trial histories beyond the head-to-head comparison: earlier trials of tirzepatide alone reported average weight reductions in the range of 16% to 22.5% depending on dose over 72 weeks [6], while earlier trials of semaglutide alone reported average reductions of roughly 15% over a slightly shorter period [7]. SURMOUNT-5 is useful precisely because it tested both molecules in the same trial, at the same time, in the same population, rather than asking readers to compare results across separate studies with different designs.

This table reflects one specific head-to-head trial's group averages. It is not a prediction for any individual and does not account for dose, prior treatment history, or other health factors a provider would weigh.

Tolerability and side effects

Head-to-head data suggests the two medications have a broadly similar side effect profile at the doses studied. In SURMOUNT-5, roughly 44% of participants in each treatment group experienced nausea, and about 25% in each group reported abdominal pain, with side effects concentrated during dose increases and generally described as mild to moderate [2]. That means the choice between them is not obviously a tradeoff between "more effective but harder to tolerate" and "gentler but weaker," at least based on this trial; the two were similar on tolerability while tirzepatide showed a larger average effect on weight.

That said, individual tolerability varies well beyond trial averages. Some people find one medication's particular side effects, timing, or dose-escalation schedule easier to manage than the other's, and a prior reaction to one does not necessarily predict the same reaction to the other. Like any prescription medication, both semaglutide and tirzepatide carry risks and possible side effects that a licensed provider should review with you before starting either one.

Price as a factor in choosing

Cost is a real, practical factor in this decision, not a side issue, since list prices, manufacturer discount programs, insurance coverage, and compounded options all differ between the two molecules and change over time. For a full breakdown of current brand and compounded pricing for both, see What GLP-1 Medications Cost in 2026.

Standard doses vs microdosing

Everything above describes standard therapeutic dosing, the amount used in the trials cited. Microdosing, using a lower dose than the standard therapeutic amount at a provider's discretion, is a separate decision from which molecule to start with, and it changes the cost and tolerability conversation without changing which medication you're on. This article is about choosing between semaglutide and tirzepatide themselves; if you're specifically weighing a lower-dose approach for either one, see Microdosing: Tirzepatide vs Semaglutide for how that decision is different from the one covered here.

How a provider actually decides

A provider deciding between semaglutide and tirzepatide is weighing several things at once: your intake questionnaire responses on health history, current medications, and prior GLP-1 use if any; contraindications, such as a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2, which apply to both medications; other conditions like gastroparesis, pancreatitis history, or gallbladder disease that may affect the choice; and practical factors like what your insurance covers or what you can access. Your selection when you start the process is a starting point and a preference, not a purchase; a provider can approve it, or suggest the other option, or a different plan entirely, based on that review. Nothing is prescribed or shipped without that review.

Common questions

Can I switch between them?

Yes, and it's a routine clinical conversation, but it should be managed by a provider rather than done on your own. Semaglutide and tirzepatide are not dose-equivalent to each other, so switching generally means restarting tirzepatide at its lowest dose rather than matching whatever dose of semaglutide you were on, and a provider will factor in how you tolerated the first medication and why you're switching [5].

Is tirzepatide stronger?

In the SURMOUNT-5 trial, tirzepatide produced a larger average weight-loss effect than semaglutide at 72 weeks, at maximum tolerated doses, with a broadly similar side effect profile [2]. "Stronger" on average in a trial is not the same as "the most effective GLP-1 for weight loss" for every individual; some people respond better to semaglutide, and average trial results describe the group, not any one person.

What if one doesn't work for me?

This happens, and it does not mean GLP-1 medications in general are not a fit for you. A provider can adjust the dose, extend the titration period, or, if appropriate, switch you to the other molecule, since they work through overlapping but not identical mechanisms. This is exactly the kind of decision that needs a licensed provider reviewing your specific response, not a self-directed switch.

Which is easier to get?

Both are FDA-approved, prescription-only medications, and legitimate access to either requires a licensed provider's review, an intake, and a prescription; neither is available without one. See How to Get Tirzepatide Online and How to Get Semaglutide Online for what that process looks like for each. For details on compounded formulations specifically, see Compounded Semaglutide Injection and Compounded Tirzepatide Injection.

Next steps

Choosing between semaglutide and tirzepatide comes down to your health history, tolerance, prior response if any, and practical factors like cost and access, not a single "best" answer. For a closer look at how doses for either medication are typically structured, see the Semaglutide & Tirzepatide Dosing Guide. The real next step is a short intake so a licensed provider can review your history and help you decide. Nothing is prescribed or shipped without that review.

Explore Luvo's Weight Loss Program.